Crystal Form Of 6-(Cyclopropanecarboxamido)-4-((2-Methoxy-3-(1-Methyl-1H-1,2,4-Triazol-3-Yl)Phenyl)Amino)-N-(Methyl-D3)Pyridazine-3-Carboxamide
Patent No. EP4284796 (titled "Crystal Form Of 6-(Cyclopropanecarboxamido)-4-((2-Methoxy-3-(1-Methyl-1H-1,2,4-Triazol-3-Yl)Phenyl)Amino)-N-(Methyl-D3)Pyridazine-3-Carboxamide") was filed by Bristol Myers Squibb on Jan 28, 2022. The application was issued on Apr 16, 2025.
Patent Summary
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4284796
- Application Number
- EP22704232A
- Filing Date
- Jan 28, 2022
- Status
- Granted And Under Opposition
- Mar 14, 2025
- Publication Date
- Apr 16, 2025
- External Links
- Slate, Register , Google Patents